Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Vascular inflammation was examined as a potential mechanism of aldosterone-mediated myocardial injury in uninephrectomized rats receiving 1% NaCl-0.3% KCl to drink for 1, 2, or 4 wk and 1) vehicle, 2) aldosterone infusion (0.75 microg/h), or 3) aldosterone infusion (0.75 microg/h) plus the selective aldosterone blocker eplerenone (100 mg. kg(-1). day(-1)). Aldosterone induced severe hypertension at 4 wk [systolic blood pressure (SBP), 210 +/- 3 mmHg vs. vehicle, 131 +/- 2 mmHg, P < 0.001], which was partially attenuated by eplerenone (SBP, 180 +/- 7 mmHg; P < 0.001 vs. aldosterone alone and vehicle). No significant increases in myocardial interstitial collagen fraction or hydroxyproline concentration were detected throughout the study. However, histopathological analysis of the heart revealed severe coronary inflammatory lesions, which were characterized by monocyte/macrophage infiltration and resulted in focal ischemic and necrotic changes. The histological evidence of coronary lesions was preceded by and associated with the elevation of cyclooxygenase-2 (up to approximately 4-fold), macrophage chemoattractant protein-1 (up to approximately 4-fold), and osteopontin (up to approximately 13-fold) mRNA expression. Eplerenone attenuated proinflammatory molecule expression in the rat heart and subsequent vascular and myocardial damage. Thus aldosterone and salt treatment in uninephrectomized rats led to severe hypertension and the development of a vascular inflammatory phenotype in the heart, which may represent one mechanism by which aldosterone contributes to myocardial disease.

[1]  J. Laragh,et al.  Malignant Hypertension Resulting from Deoxycorticosterone Acetate and Salt Excess: ROLE OF RENIN AND SODIUM IN VASCULAR CHANGES , 1975, Circulation research.

[2]  E. Fleck,et al.  Myocardial osteopontin expression is associated with left ventricular hypertrophy. , 1997, Circulation.

[3]  M. Noda,et al.  Osteopontin expression and function: Role in bone remodeling , 1998, Journal of cellular biochemistry. Supplement.

[4]  K. Weber,et al.  Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. , 1992, Cardiovascular research.

[5]  I. Rodger,et al.  Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. , 1998, Circulation.

[6]  J. Balligand,et al.  Glucocorticoids Increase Osteopontin Expression in Cardiac Myocytes and Microvascular Endothelial Cells , 1995, The Journal of Biological Chemistry.

[7]  D. Graves,et al.  Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. , 1992, Journal of immunology.

[8]  W A Hsueh,et al.  Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. , 1996, The Journal of clinical investigation.

[9]  C. Stier,et al.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. , 1998, Hypertension.

[10]  H. Sigusch,et al.  Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy. , 1998, Cytokine.

[11]  A. O’Regan,et al.  Osteopontin augments CD3‐mediated interferon‐γ and CD40 ligand expression by T cells, which results in IL‐12 production from peripheral blood mononuclear cells , 2000, Journal of leukocyte biology.

[12]  N. Farman,et al.  Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. , 1995, Circulation.

[13]  M. Glimcher,et al.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. , 2000, Science.

[14]  B. Rollins,et al.  Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. , 1991, Blood.

[15]  E. Benveniste,et al.  Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions , 2000, Oncogene.

[16]  C. Stier,et al.  Downloaded from http://hyper.ahajournals.org / by guest on February 21, 2013Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats , 2022 .

[17]  H. Rennke,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy* , 2022 .

[18]  S. Schwartz,et al.  Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. , 1994, Circulation research.

[19]  J. Delyani.  Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. , 2000, Kidney international.

[20]  S. Schwartz,et al.  Osteopontin Expression in Cardiovascular Diseases a , 1995, Annals of the New York Academy of Sciences.

[21]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[22]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[23]  D. Ganten,et al.  Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. , 1999, Hypertension.

[24]  C. Delcayre,et al.  Biological determinants of aldosterone-induced cardiac fibrosis in rats. , 1995, Hypertension.

[25]  H. Shimokawa,et al.  Role of Monocyte Chemoattractant Protein-1 in Cardiovascular Remodeling Induced by Chronic Blockade of Nitric Oxide Synthesis , 2000, Circulation.

[26]  K. Mahboubi,et al.  Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. , 2000, Circulation research.

[27]  M. Young,et al.  The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. , 1996, The American journal of physiology.

[28]  HiroakiShimokawa,et al.  Role of Monocyte Chemoattractant Protein-1 in Cardiovascular Remodeling Induced by Chronic Blockade of Nitric Oxide Synthesis , 2000 .

[29]  K. Ley,et al.  Molecular mechanisms of leukocyte recruitment in the inflammatory process. , 1996, Cardiovascular research.

[30]  C. Gomez-Sanchez,et al.  An alternatively spliced rat mineralocorticoid receptor mRNA causing truncation of the steroid binding domain , 2000, Molecular and Cellular Endocrinology.

[31]  N. Aiyar,et al.  Monocyte Chemoattractant Protein-1 is Upregulated in Rats With Volume-Overload Congestive Heart Failure , 1999, Circulation.

[32]  J. Van Peteghem.  [General adaptation syndrome and diseases of adaptation]. , 1950, Gynecologie pratique.

[33]  D. Fitzgerald,et al.  Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. , 2000, Circulation.

[34]  T. Candresse,et al.  Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[35]  I. Miyamori,et al.  Vascular aldosterone in genetically hypertensive rats. , 1997, Hypertension.

[36]  S. Friedman,et al.  THE EFFECT OF DESOXYCORTICOSTERONE ACETATE ON BLOOD PRESSURE, RENAL FUNCTION, AND ELECTROLYTE PATTERN IN THE INTACT RAT , 1948, The Journal of experimental medicine.

[37]  S. Friedman,et al.  OBSERVATIONS ON THE RÔLE OF THE RAT KIDNEY IN HYPERTENSION CAUSED BY DESOXYCORTICOSTERONE ACETATE , 1949, The Journal of experimental medicine.